Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 2Phase 2/3 2Phase 1 2Phase NA 1Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Multiple Endocrine Neoplasia Type 1 1Fatigue 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × Methylphenidate × Clear all
NCT02361125 2022-01-04

Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate

M.D. Anderson Cancer Center

Phase 1 Completed
31 enrolled

Fatigue

NCT01202734 2014-05-16

A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 1 Completed
10 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡